FDA Expands Use of Symdeko for Cystic Fibrosis to Younger Children - Medscape

FDA Expands Use of Symdeko for Cystic Fibrosis to Younger Children  Medscape

The FDA has approved tezacaftor/ivacaftor tablets for use in children as young as 6 years with cystic fibrosis with certain genetic mutations in the CFTR gene.